Generated by AI
Virtus Biotech Clinical Trials ETF is an exchange-traded fund designed to track an equally weighted index of U.S.-listed biotechnology companies with lead drugs in Phase 1, Phase 2, or Phase 3 clinical trials. The fund provides targeted exposure to the clinical-stage biotech segment, which is centered on companies developing experimental therapies across areas such as oncology, immunology, rare diseases, and other health care specialties. Its portfolio typically includes a diversified mix of firms at different stages of drug development, giving investors broad access to the innovation pipeline rather than a single company or treatment area. By focusing on clinical-trials biotechnology, Virtus Biotech Clinical Trials ETF plays a specialized role in the market as a thematic health care fund that concentrates on research-driven companies with products still under development.
Summary of Apr 9's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about BBC also mention these. Each card shows that asset’s own numbers for the past 24 hours.